Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

User Fee Delinquencies Rising At US FDA After PDUFA Redesign

Executive Summary

Prescription drug user fee "receivables" nearly doubled in FY 2018, but the US FDA is not worried.

You may also be interested in...



PDUFA VII: FDA, Industry Agree To Set Minimum Carryover Balance Levels

The minimum total will increase from eight weeks of operating expenses in FY 2023 to 10 weeks by FY 2025.

US Biosimilar Fee Collections Fall Short

A lower-than-expected number of fee-paying application submissions in FY 2018 resulted in the agency spending approximately $9.7m more than anticipated from its user fee carryover balance, leading to a reset of spend-down targets for the remainder of BsUFA II.

After Biosimilar Fee Collections Fall Short, US FDA Modifies Carryover Spend-Down Plan

A lower-than-expected number of fee-paying application submissions in FY 2018 resulted in the agency spending approximately $9.7m more than anticipated from its user fee carryover balance, leading to a reset of spend-down targets for the remainder of BsUFA II.

Related Content

Topics

UsernamePublicRestriction

Register

PS140941

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel